Table 1.

Worldwide PROTAC projects in the clinical stage (Data before June 2022).

Degrader	Target	Company	E3 ligase	Highest phase	Ref.
ARV-110	AR	Arvinas	CRBN	Phase VII	[65]
ARV-471	ER	Arvinas; Pizer	CRBN	Phase VII	[66]
CFT7455	IKZF3, IKZF1	C4 Therapeutics	CRBN	Phase VII	[67]
AC0682	ER α	Accutar Biotech	CRBN	Phase I	[68]
AC0176	AR	Accutar Biotech	Undisclosed	Phase I	[68]
ARV-766	AR	Arvinas	Undisclosed	Phase I	[69]
BGB-16673	BTK	Beigene	CRBN	Phase I	[70]
CC-94676	AR	BMS	CRBN	Phase I	[71]
DT2216	BCL-XL	Dialectic Therapeutics； University of Florida	VHL	Phase I	[72]
FHD-609	BRD9	Foghorn Therapeutics	Undisclosed	Phase I	[73]
HP518	AR	Hinova	Undisclosed	Phase I	[74]
KPG-818	IKZF 1/3	Kangpu	CRBN	Phase Ib/2a	[75]
KPG-121	IKZF 1/3; CK 1a	Kangpu	CRBN	Phase I	[76]
KT-333	STAT3	Kymera	Undisclosed	Phase I	[77]
KT-413	IRK4	Kymera	CRBN	Phase I	[78]
KT-474	IRK4	Kymera; Sanofi	Undisclosed	Phase I	[79]
NX-2127	BTK	Nurix Therapeutics	CRBN	Phase I	[80]
NX-5948	BTK	Nurix Therapeutics	CRBN	Phase I	[81]
AC0676	BTK	Accutar Biotech	Undisclosed	IND-Enabling	[68]
CFT8634	BRD9	C4 Therapeutics	CRBN	IND-Enabling	[82]
CFT8919	EGFR-L858R	C4 Therapeutics	CRBN	IND-Enabling	[83]
CG001419	TRK	Cullgen	CRBN	IND-Enabling	[84]